期刊文献+

RP-HPLC法测定奥利司他原料药的含量 被引量:1

Content Determination of Orlistat Substance by RP-HPLC Method
下载PDF
导出
摘要 建立奥利司他原料药的含量测定方法。采用高效液相色谱法,Agilent SB-C18色谱柱(25cm×4.6mm,5μm),流动相为甲醇∶水(90∶10);柱温为30℃;流速1.0mL·min^-1;进样量20μL。紫外检测器,检测波长为190 nm。主成分奥利司他在0.4-0.6 mg/mL浓度范围内线性关系良好,相关系数r〉0.999,在相对浓度80%、100%、120%范围内的平均回收率较高。该检测方法精密度及准确度较高,可订入奥利司他原料药的质量标准中,作为含量测定的控制方法。 A high performance liquid chromatography method was established to determine the contents of orlistat substance. An isocratic separation was achieved by an agilent SB - C18 column at a flow rate of 1.0 mL/min. The mobile phase consisted of methanol - water 90: 10(v/v). The UV detector was used at 190 nm. Complete separation was achieved for orlistat and other impurities. The method was linear over the concentration range of 0.4 - 0.6 mg/mL ( r 〉 0. 999) and the recoveries were accorded with prescribe. The HPLC method has the requisite accuracy and selectivity for the content determination of orlistat tablet.
出处 《山东化工》 CAS 2015年第11期64-65,共2页 Shandong Chemical Industry
关键词 奥利司他 原料药 高效液相色谱法 含量 orlistat tablet HPLC content
  • 相关文献

参考文献4

二级参考文献22

  • 1[1]Eckel RH. Obesity and heart disease[J]. Circulation,1997,96(9) :3248 - 3250.
  • 2[2]Meigs J, Nathan D, Wilson P, et al. Metabolic risk factors worsencontinuously across the spectrum of nondiabetie glucose tolerance[J]. Ann Inter Med, 1998,28(7): 524 - 533.
  • 3[3]Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine [J]. N Engl JMed, 1997,337(9) :581 - 588.
  • 4[4]Stone NJ, Kushner R. Effects of dietary modification and treatment of obesity[J]. Med Clin North Am ,2000,84(1) :95 - 102.
  • 5[5]Xavier F,Sunyer PI,Laferrere B,et al. Obesity-a modern-day epidemic[J]. J Clin Endocrinol Metab, 1999,84 (1): 3 - 12.
  • 6[6]Sjostrom L, Rissanen A, Adersen T, et al. Randomised placebocontrolled trial of orlistat for weight loss and prevention of weightregain in obese patients[J]. Lancet, 1998, 352 (9123): 167 -173.
  • 7[7]Davidson MH, Hauptman J, DiGirolamo M. Weight control andrisk factors reduction in obese subjects treated for 2 years withorlistat[J]. JAMA, 1999,281(3):235 - 242.
  • 8[8]Zhi J, Melia AT, Eggers H, et al. Review of limited systemic absorption of orlistat,a lipase inhibitor,in healthy human volunteers[J]. J Clin Pharmacol, 1995,35 (11):1103 - 1198.
  • 9Schwartz TL, Beale M. Pharmacokinetics and drug interactions of the sedative hypnotics. Psychopharmacol Bull,2003,37 ( 1 ) :5.
  • 10Patrick K Bermett,Yu -Tsyir Li,Richard Edom,et al . Quantitative determination of orlistat ( Tetrahydrolipostatin, Ro 18 - 0647 ) in human plasma by high - performance liquid chromatography coupled with ionspray tandem mass spectrometry. J Mass Spectrom, 1997,32:739.

共引文献15

同被引文献9

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部